Jennifer Fillaus, DO
Internal Medicine · Yankton, SDNPI 1760696967
Payments from drug & device makers
What this record shows
This record is dominated by education: $120 of the $151 with a category attached, or 79.3%. Genentech USA, Inc. accounts for 66.3% of it on its own, with 3 other manufacturers making up the rest. Reporting peaked in 2019 at $100 and has fallen 66.5% since, to $34 in 2025.
Across 7 payments — averaging $21.54 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Genentech USA, Inc.$100
- Otsuka America Pharmaceutical, Inc.$29
- AstraZeneca$17
- Travere Therapeutics, Inc.$5
What the payments were for
- Food & beverage$3121%
- Education$12079%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Genentech USA, Inc. | 1 | $100 |
| Otsuka America Pharmaceutical, Inc. | 2 | $29 |
| AstraZeneca | 1 | $17 |
| Travere Therapeutics, Inc. | 3 | $5 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- Rituxan$100
How this compares
$151 in reported general payments places this provider in the 65th percentile of 178 internal medicine providers in South Dakota.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 42 | $30,562 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 15 | $9,297 |
| Breo ElliptaFluticasone/Vilanterol | 11 | $4,275 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 20 | $3,569 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 21 | $2,116 |
| Humalog Kwikpen U-100Insulin Lispro | 11 | $1,655 |
| Atorvastatin Calcium | 128 | $1,370 |
| Mirtazapine | 59 | $1,188 |
| Amlodipine Besylate | 191 | $951 |
| Methenamine Hippurate | 11 | $827 |
| Nano 2nd Gen Pen NeedlePen Needle, Diabetic | 14 | $819 |
| Potassium Chloride | 85 | $745 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 31 | $642 |
| Cefdinir | 46 | $637 |
| Omeprazole | 77 | $600 |
Paid to pharmacies, not to this prescriber.
Other internal medicine in Yankton
- Amanda SedlacekYankton$326
- Tyler HansonYankton$292
- Sherlon SinclairYankton$149
- Jennifer MayRapid City$52K
- Richard BeasleyRapid City$25K
- Issam TurkRapid City$14K
- Janell PowellSioux Falls$7K
- Maaz BadshahSioux Falls$6K
- Robert AllisonPierre$6K
- Travis HendersonMobridge$6K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.